Jean Jacques Bienaime - 21 Dec 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
21 Dec 2023
Net transactions value
-$308,900
Form type
4
Filing time
22 Dec 2023, 17:14:23 UTC
Previous filing
09 Nov 2023
Next filing
12 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $631,000 +10,000 +2.4% $63.10 435,112 21 Dec 2023 Direct F1
transaction BMRN Common Stock Sale $939,900 -10,000 -2.3% $93.99 425,112 21 Dec 2023 Direct F1
holding BMRN Common Stock 247,333 21 Dec 2023 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 21 Dec 2023 Shares held as UTMA custodian for child 1
holding BMRN Common Stock 100 21 Dec 2023 Shares held as UTMA custodian for child 2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -10,000 -5.2% $0.000000 181,000 21 Dec 2023 Common Stock 10,000 $63.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.